Eli Lilly and Company
LLY
$659.00
$19.573.06%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.56B | 12.73B | 13.53B | 11.44B | 11.30B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.56B | 12.73B | 13.53B | 11.44B | 11.30B |
| Cost of Revenue | 2.45B | 2.22B | 2.40B | 2.17B | 2.17B |
| Gross Profit | 13.11B | 10.50B | 11.13B | 9.27B | 9.13B |
| SG&A Expenses | 2.65B | 2.36B | 2.31B | 1.98B | 2.00B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.43B | 7.32B | 7.74B | 6.89B | 6.88B |
| Operating Income | 7.13B | 5.41B | 5.80B | 4.55B | 4.42B |
| Income Before Tax | 6.78B | 3.46B | 5.04B | 1.59B | 3.52B |
| Income Tax Expenses | 1.12B | 696.80M | 628.90M | 618.10M | 550.20M |
| Earnings from Continuing Operations | 5.66B | 2.76B | 4.41B | 970.30M | 2.97B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.66B | 2.76B | 4.41B | 970.30M | 2.97B |
| EBIT | 7.13B | 5.41B | 5.80B | 4.55B | 4.42B |
| EBITDA | 7.60B | 5.87B | 6.28B | 5.02B | 4.83B |
| EPS Basic | 6.30 | 3.07 | 4.88 | 1.08 | 3.29 |
| Normalized Basic EPS | 4.74 | 3.62 | 3.87 | 3.04 | 2.96 |
| EPS Diluted | 6.29 | 3.06 | 4.88 | 1.07 | 3.28 |
| Normalized Diluted EPS | 4.73 | 3.62 | 3.87 | 3.03 | 2.95 |
| Average Basic Shares Outstanding | 897.90M | 898.70M | 903.16M | 901.00M | 900.90M |
| Average Diluted Shares Outstanding | 899.80M | 900.60M | 903.16M | 905.00M | 904.20M |
| Dividend Per Share | 1.50 | 1.50 | 1.30 | 1.30 | 1.30 |
| Payout Ratio | 23.80% | 48.79% | 26.49% | 120.63% | 39.51% |